EMA's Restriction Of Multaq Indication Could Spell Death Knell For The Drug In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
While giving it a positive risk/benefit balance, EMA says other anti-arrhythmic medicines should be considered before Sanofi's Multaq, potentially heralding its demise in Europe.
You may also be interested in...
Multaq REMS May Be Revamped As Label Adds New Risks
After several years of regulatory struggles Sanofi’s anti-arrhythmic Multaq finally got to market. But results from a new study have drawn attention to safety problems in higher-risk patients and could damage the drug’s commercial opportunity.
European HTA: Cancer Drugs Suffer At NICE, Whilst IQWiG And HAS Also Tighten Purse Strings
Economic austerity and the resulting pressure on health care spend leaves little room for maneuver among Europe’s health technology assessment agencies.
Sanofi Avoids Patent Cliff For Now, Returns to Growing Sales And Profits In Third Quarter
Sanofi's Q3 sales grow by 10% and net income by 4.1% as Genzyme acquisition compensates for increasing generic competition to leading products.